Mrs. Remmick is 72 years old, and suffers acute and chronic sinus infections. Her Otolaryngologist always prescribes Telquin (Gatifloxacin) to eradicate the disease. At the same time, her internist is treating her for hypoglycemia, and her medical condition fails to improve. Recently, Dr. Internist discovers an article in a medical publication that links Gatifloxacin to hypoglycemia in the elderly.
According to the two Canadian studies published in the New England Journal of Medicine, the risk of developing hypoglycemia in the elderly, who takes Gatifloxacin, is substantially higher compared to the rest of the population.
Hypoglycemia is a deficiency of sugar in the blood… a condition in which glucose in the blood is abnormally low.
Gatifloxacin (Tequin, Bristol-Myers Squibb) is a quinolone antibotic used to treat infections of the sinuses, lungs, urinary tract, and some sexually transmitted diseases. The drug met the approval of the Food and Drug Administration (FDA) in 1999.
Since Gatifloxacin offers very little therapeutic advantages over alternate antibiotics that have no risk of hypoglycemia, elderly people should avoid Gatifloxacin.
Dr. Internist conveyed the good news to Mrs. Rimmick’s Otolaryngologist, who immediately discontinue prescribing Gatifloxacin for his older patients.